perceived interdependence of sexual intercourse and drug use | ||||||||
---|---|---|---|---|---|---|---|---|
weak groupa | strong groupb | Total | Analysis | |||||
n = 143 | n = 297 | n = 440 | Statistic | p-value* | ||||
Age (median, Q1-Q3) | 39 | (32–46) | 42 | (36–48) | 42 | (34–47) | U = 24,555.000 | 0.008 |
Heterosexual: n (%) | 127 | (88.8) | 251 | (84.5) | 378 | (85.9) | 0.245 | |
Completed high school: n (%) | 67 | (46.9) | 126 | (42.4) | 193 | (43.9) | 0.412 | |
Unemployed: n (%) | 111 | (77.6) | 214 | (72.1) | 325 | (73.9) | 0.247 | |
Living condition: n (%) | ||||||||
Living in a dormitory (rehabilitation center) | 117 | (81.8) | 222 | (74.7) | 339 | (77.0) | 0.116 | |
Daycare | 11 | (7.7) | 30 | (10.1) | 41 | (9.3) | 0.486 | |
Undergoing training as rehabilitation staff | 15 | (10.5) | 45 | (15.2) | 60 | (13.6) | 0.235 | |
Chronic disease (physical disease): n (%) | 22 | (15.4) | 74 | (25.2) | 96 | (22.0) | 0.026 | |
Primary drug: n (%) | ||||||||
Methamphetamine | 56 | (39.2) | 214 | (72.1) | 270 | (61.4) | < 0.001 | |
NPS | 22 | (15.4) | 38 | (12.8) | 60 | (13.6) | 0.461 | |
Organic solvent | 14 | (9.8) | 12 | (4.0) | 26 | (5.9) | 0.029 | |
Marijuana | 11 | (7.7) | 13 | (4.4) | 24 | (5.5) | 0.179 | |
Prescription drugs | 17 | (11.9) | 7 | (2.4) | 24 | (5.5) | < 0.001 | |
Over-the-counter drugs | 14 | (9.8) | 6 | (2.0) | 20 | (4.5) | 0.001 | |
Others (cocaine, heroin, MDMA, gas) | 9 | (6.3) | 7 | (2.4) | 16 | (3.6) | 0.055 | |
Drug-related criminal history: n (%) | 40 | (28.0) | 163 | (54.9) | 203 | (46.1) | < 0.001 | |
Never experienced treatment: n (%) | 22 | (15.5) | 64 | (21.8) | 86 | (19.7) | 0.157 | |
Consistent condom use under the influence of drugs: n (%) | ||||||||
Always uses condoms | 66 | (46.2) | 38 | (12.8) | 104 | (23.7) | < 0.001 | |
Sometimes a non-condom user | 27 | (18.9) | 50 | (16.9) | 77 | (17.5) | 0.595 | |
Mostly a non-condom user | 50 | (35.0) | 208 | (70.3) | 258 | (58.8) | < 0.001 | |
Injecting and sharing needles during drug use: n (%) | ||||||||
None | 74 | (52.9) | 60 | (20.5) | 134 | (31.0) | < 0.001 | |
Only experienced injection | 16 | (11.4) | 46 | (15.8) | 62 | (14.4) | 0.245 | |
Experienced injection and sharing needles | 50 | (35.7) | 186 | (63.7) | 236 | (54.6) | < 0.001 | |
Diagnosis of sexually transmitted disease in lifetime: n (%) | ||||||||
Hepatitis A | 0 | (0.0) | 1 | (0.3) | 1 | (0.2) | 1.000 | |
Hepatitis B | 1 | (0.7) | 18 | (6.3) | 19 | (4.5) | 0.006 | |
Hepatitis C | 19 | (13.6) | 92 | (32.2) | 111 | (26.1) | < 0.001 | |
Gonorrhea | 6 | (4.3) | 30 | (10.5) | 36 | (8.5) | 0.040 | |
Chlamydia | 7 | (5.0) | 22 | (7.7) | 29 | (6.8) | 0.413 | |
Syphilis | 2 | (1.4) | 19 | (6.6) | 21 | (4.9) | 0.017 | |
HIV | 0 | (0.0) | 18 | (6.3) | 18 | (4.2) | 0.001 | |
Never diagnosis of STD | 110 | (78.6) | 139 | (48.6) | 249 | (58.5) | < 0.001 | |
DAST-20 total score (median, Q1-Q3) | 13.0 | (10–16) | 15.0 | (12–17) | 14.0 | (12–16) | U = 25,873.500 | < 0.001 |